New Combo Therapy for Untreated CLL Tops SPT Week in Review

5. FDA OKs Relaunch of Novel Intravenous Immune Globulin Product

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease. Read more.
 

4. FDA Grants Breakthrough Designation to Treatment for Kaposi Sarcoma

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status. Read more.
 

3. FDA OKs First Anti-PD-L1 Therapy in Combo Regimen for Advanced Kidney Cancer

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma. Read more.

2. FDA Committee Votes Against Quizartinib Approval for Acute Myeloid Leukemia

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study. Read more.

1. FDA Approves Combo Therapy for Untreated Chronic Lymphocytic Leukemia

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia. Read more.

 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$